Related Experiment Video
Updated: Mar 11, 2026
03:52
The Creation of a Rat Model for Osteosarcopenia via Ovariectomy
Published on: February 21, 2025
1.4K
Pathogenesis and Management of Sarcopenia
Robinder J S Dhillon1, Sarfaraz Hasni1
1National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, 9000 Rockville Pike, Building 10, Room Number 3-2340, Bethesda, MD 20892, USA.
Clinics in Geriatric Medicine
|November 26, 2016
Summary
Sarcopenia, the loss of muscle mass and strength in older adults, is under-recognized and poorly managed. Current treatments focus on physical therapy, with no approved medications available.
Area of Science:
- Gerontology
- Muscle physiology
- Public health
Background:
- Sarcopenia, characterized by age-related loss of muscle strength and mass, significantly impacts elderly health, increasing morbidity, mortality, and healthcare costs.
- Despite its clinical significance, sarcopenia is frequently under-recognized and inadequately managed in clinical settings.
- Challenges in diagnosis, including the lack of standardized criteria and accessible testing, contribute to its poor management.
Purpose of the Study:
- To highlight the clinical importance and challenges in managing sarcopenia in the elderly.
- To underscore the current limitations in diagnostic tools and treatment options for sarcopenia.
Main Methods:
- Literature review on sarcopenia prevalence, impact, diagnosis, and management.
- Analysis of current clinical practices and research trends in sarcopenia.
Main Results:
- Sarcopenia is a growing concern in aging populations, affecting health outcomes and healthcare expenditure.
- Existing management strategies primarily involve physical therapy, such as muscle strengthening and gait training.
- There are currently no pharmacologic treatments available for sarcopenia.
Conclusions:
- Sarcopenia requires greater clinical attention and the development of uniform diagnostic criteria.
- Future research should focus on developing effective pharmacologic interventions to address sarcopenia.
- Improved recognition and management strategies are crucial for mitigating the impact of sarcopenia on the elderly population.
Related Concept Videos
01:29Bone Disorders
5.8K
Aging and its effect on bone remodeling is the most common cause of bone disorders. In young and healthy people, bone deposition and resorption happen at an equal rate to maintain optimal bone health.
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...
5.8K
01:21Overview of Protein Metabolism
4.4K
Proteins are broken down into amino acids during digestion. Unlike fats and carbohydrates, which are stored for later use, proteins are not. Instead, amino acids are either used to produce ATP through oxidation or contribute to the creation of new proteins for the growth and repair of the body. Any surplus amino acids from the diet are converted into glucose or triglycerides rather than excreted.
Amino acids play various roles in the body once they are absorbed into cells. They are restructured...
Amino acids play various roles in the body once they are absorbed into cells. They are restructured...
4.4K
01:15Parkinson's Disease: Overview
2.3K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
2.3K
01:26Cross-bridge Cycle
124.0K
As muscle contracts, the overlap between the thin and thick filaments increases, decreasing the length of the sarcomere—the contractile unit of the muscle—using energy in the form of ATP. At the molecular level, this is a cyclic, multistep process that involves binding and hydrolysis of ATP, and movement of actin by myosin.
124.0K
03:03mTOR Signaling and Cancer Progression
5.0K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
5.0K
01:29Cardiomyopathy VI: Nursing Management
433
Assessment: Nursing management of patients with cardiomyopathy begins with a thorough assessment of the patient's history, including a family history of cardiomyopathy or sudden cardiac death, personal history of heart disease, hypertension, diabetes, and any alcohol consumption or drug use.During the physical examination, assess vital signs, look for signs of heart failure (such as edema, jugular venous distention, and cyanosis), auscultate for abnormal heart sounds (like murmurs and gallops),...
433